Recent Finacing
Recent Raise
Deka Biosciences develops disease-specific Diakines—dual-cytokine therapeutic proteins—for targeted delivery to affected tissues, using precision-medicine patient selection and advancing IND-stage oncology (DK210 EGFR) and inflammatory programs.
